DECEMBER 17, 2021

Data Point to an Edge for PCV13 Against Vaccine-Type Pneumococcal Pneumonia

By David Wild

A systematic review and meta-analysis of six studies concluded that the 13-valent pneumococcal conjugate vaccine (PCV13) is more effective than the 23-valent pneumococcal polysaccharide vaccine (PPSV23) against vaccine-type pneumococcal pneumonia in older adults. 

Although the research was limited by variations in the design of studies it included, a pooled analysis showed that PPSV23 was only 35% efficacious and effective against pneumococcal pneumonia.

“Pooled [vaccine